Financial Performance - The company reported a net profit attributable to shareholders of -15.76 million yuan for 2024, leading to a decision not to distribute cash dividends or increase capital reserves [8]. - The company's operating revenue for 2024 was CNY 242.31 million, a decrease of 6.16% compared to CNY 258.21 million in 2023 [24]. - The net profit attributable to shareholders for 2024 was a loss of CNY 15.76 million, a decline of 298.78% from a profit of CNY 7.93 million in 2023 [24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 19.25 million in 2024, compared to a profit of CNY 3.70 million in 2023, marking a decline of 620.88% [24]. - The company reported a decrease of 4.51% in revenue after excluding non-core business income, totaling CNY 234.95 million in 2024 [24]. - The company experienced increased costs due to credit impairment losses and legal consultation fees related to executive events [4]. - The company faced a decline in revenue and profit due to industry demand fluctuations and increased competition, resulting in a decrease in product prices [4]. - The company reported a significant increase in asset impairment losses, which rose by 100.06% year-on-year [152]. - The company experienced a 39.62% decline in investment income, totaling CNY 1.62 million [149]. - The company reported a 90.52% decrease in non-operating expenses, amounting to CNY 294,250.75 [149]. Research and Development - The company plans to continue focusing on its core business and enhance its competitive edge by increasing R&D investment [4]. - R&D investment for 2024 was 62.47 million RMB, accounting for 25.78% of the current operating revenue [35]. - Total R&D investment for the year was CNY 62.47 million, a decrease of 10.50% compared to the previous year, with R&D expenses accounting for 25.78% of operating revenue [113]. - The number of R&D personnel decreased from 99 to 76, with R&D personnel now representing 18.95% of the total workforce [121]. - The average salary of R&D personnel increased to 25.38 thousand RMB, compared to 20.09 thousand RMB in the previous period [121]. - The company has established a strong core R&D team, with key personnel having extensive experience and educational backgrounds from prestigious institutions [123]. - The company has developed an AI-based multi-omics analysis platform utilizing a database of over 10,000 patients, enhancing its data-driven decision-making capabilities [124]. - The company is focusing on blood cancer precision diagnostics and related minimal residual disease detection, pausing some projects in solid tumors and pathogen microbiology [120]. Product Development and Market Position - The company is committed to the national strategy of "precision medicine" by providing self-branded molecular diagnostic reagents and services [4]. - The company has developed 107 in vitro diagnostic reagent kits, with 31 classified as Class III medical devices, covering blood diseases, solid tumors, and infectious diseases [64]. - The company has launched several unique diagnostic products, including the first approved molecular diagnostic kits for leukemia and solid tumors in China, significantly enhancing its market position [64][65]. - The company has established partnerships with multiple hospitals for various research projects, including the molecular typing of AML and B-ALL, enhancing its research capabilities [50]. - The company achieved a daily testing capacity of 20,000 samples in its upgraded intelligent laboratory, significantly improving testing efficiency [55]. - The company has received approval for multiple gene mutation detection kits, including a kit for acute myeloid leukemia (AML) with a market size of 3,000 million RMB, and a kit for diffuse large B-cell lymphoma with a market size of 5,000 million RMB [117]. - The company is actively pursuing academic collaborations, with multiple research papers published in reputable journals, enhancing its market presence and credibility [38][39][40]. Market Challenges and Risks - The company faces risks of declining revenue and profit due to industry demand fluctuations and increased competition, with potential short-term performance pressure [131]. - The company is at risk of new product development failures due to high costs and long development cycles, which could impact its competitive edge [133]. - The company must maintain quality control across its expanding operations to avoid product quality risks that could harm its reputation [139]. - The company has 12 third-class medical device products pending registration, with potential delays due to regulatory changes posing a risk to timely market entry [134]. Operational Efficiency - The net cash flow from operating activities increased by 33.00% to CNY 59.98 million in 2024, compared to CNY 45.10 million in 2023 [24]. - The company’s financial statements received an unqualified audit opinion with emphasis on certain matters [6]. - The company has continuously updated its internal control systems to enhance governance and risk management practices [56]. - The company is continuing to utilize its raised funds under the supervision of Guotai Junan Securities Co., Ltd. for ongoing projects [23]. Sales and Revenue Breakdown - Revenue from leukemia molecular detection kits was 137.78 million RMB, a year-on-year decrease of 3.49% [34]. - Revenue from lymphoma rearrangement detection kits increased by 12.55% to 36.66 million RMB [34]. - The company’s testing services revenue was 20.65 million RMB, down 12.08% year-on-year, while research services revenue fell by 24.97% to 4.61 million RMB [153]. - The gross margin for in vitro diagnostic products was 75.90%, an increase of 1.04 percentage points compared to the previous year [154]. - The company reported a significant increase in accounts receivable by 1,355.50% to 46.86 million RMB compared to the previous year [176]. Strategic Partnerships and Collaborations - The company collaborates with top hospitals and universities, enhancing its brand influence and recognition in the molecular diagnostics field [130]. - The company has established stable partnerships with over 70 hospitals for its early-stage molecular diagnostic products for solid tumors [81]. - The company is focusing on strategic partnerships with leading reagent companies to leverage advanced technology platforms for market entry [102].

地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2022 年限制性股票激励计划作废部分已授予 尚未归属的限制性股票的 法律意见书 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2022 年限制性股票激励计划作废部分已授予 尚未归属的限制性股票的 法律意见书 案号：01F20221079 致：上海睿昂基因科技股份有限公司 上海市锦天城律师事务所（以下简称"锦天城"或"本所"）接受上海睿昂 基因科技股份有限公司（以下简称"公司"或"睿昂基因"）的委托，担任公司 "2022 年限制性股票股权激励计划"（以下简称"本激励计划"或"本次激励 计划"）的法律顾问，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、中国证券监督管理委 员会（以下简称"中国证监会"）、《上市公司股权激励管理办法》（以下简称 "《管理办法》"）、《上海证券交易所科创板股票上市规 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海睿昂基因科技股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日 召开第三届董事会第二次会议和第三届监事会第二次会议，审议通过了《关于作 废 2022 年限制性股票激励计划部分已授予尚未归属的限制性股票的议案》，现将 有关事项说明如下： 一、公司 2022 年限制性股票激励计划已履行的决策程序和信息披露情况 1、2022 年 3 月 10 日，公司召开第二届董事会第二次会议，审议通过了《关 于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年限制性股票激励计划实施考核管理办法>的议案》《关于提请公司股东大会授权 董事会办理股权激励相关事宜的议案》等相关议案。公司独立董事就激励计划相 关议案发表了独立意见。 同日，公司召开第二届监事会第二次会议，审议通过了《关于公司<2022 年 限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年限制性股票 激励计划实施考核管理办法>的议案》《关于核实公司<2022 年限制性股票 ...

| 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.2800 | 0.1400 | -300 | 0.7300 | | 每股净资产（元） | 16.28 | 16.93 | -3.84 | 16.86 | | 每股公积金(元) | 13.11 | 13.17 | -0.46 | 13.05 | | 每股未分配利润(元) | 2.48 | 2.76 | -10.14 | 2.81 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.42 | 2.58 | -6.2 | 4.24 | | 净利润(亿元) | -0.16 | 0.08 | -300 | 0.4 | | 净资产收益率(%) | -1.71 | 0.84 | -303.57 | 4.43 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 2738.78万股，累计占流通股比： 49.04%，较上期变化： -21 ...

睿昂基因公告，2024年营业收入为2.42亿元，同比下降6.16%；归属于上市公司股东的净亏损1576.45万 元，去年同期净利润793.07万元；基本每股收益-0.28元／股。2024年度拟不派发现金红利，不送红股， 不以资本公积转增股本，剩余未分配利润1.38亿元滚存至下一年度。 ...

Company Overview - Ruiang Gene's closing price on April 16 was 20.61 yuan, down 2.14%, with a latest price-to-book ratio of 1.24 and a total market capitalization of 1.151 billion yuan [1] - As of September 30, 2024, Ruiang Gene had 4,658 shareholders, an increase of 641 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - The main business of Shanghai Ruiang Gene Technology Co., Ltd. includes the research, production, sales, and scientific services of in vitro diagnostic products, with a focus on molecular diagnostic reagents [1] - The company's flagship product, the Bai Ruida leukemia testing kit, is the most comprehensive in terms of fusion gene types approved for sale in China, allowing the company to maintain a leading position in the domestic leukemia molecular diagnostics market [1] - Ruiang Gene has received several honors, including "Shanghai Specialized and Innovative Enterprise" and "Fengxian District Technology Small Giant Enterprise," and has undertaken multiple major scientific research projects led by various government departments [1] Financial Performance - In the latest quarterly report for Q3 2024, the company achieved operating revenue of 190 million yuan, a year-on-year decrease of 4.62%, and a net profit of 5.7273 million yuan, down 69.58% year-on-year, with a gross profit margin of 76.08% [1] Industry Comparison - Ruiang Gene's price-to-earnings ratio (TTM) is -79.59, with a price-to-earnings ratio (static) also at -79.59, and a price-to-book ratio of 1.24, compared to the industry average P/E ratio of 45.94 and a P/B ratio of 4.71 [2] - The industry median P/E ratio is 29.64, with a median P/B ratio of 2.35, indicating that Ruiang Gene is significantly below industry averages in terms of profitability metrics [2]

Financial Performance - Total revenue for 2024 was RMB 241.87 million, a decrease of 6.33% compared to the previous year[2] - Net profit attributable to the parent company was -RMB 14.46 million, a decline of 282.38% year-on-year[2] - Basic earnings per share were -RMB 0.26, down 285.71% from the previous year[2] - The company's equity attributable to shareholders decreased by 3.72% to RMB 910.56 million[3] Assets and Impairments - Total assets at the end of the reporting period were RMB 997.11 million, a decrease of 4.51% from the beginning of the period[2] - The company recognized goodwill impairment of RMB 14.30 million, an increase of RMB 6.81 million compared to the previous year[6] - Credit impairment losses on accounts receivable increased by RMB 3.80 million due to slower customer payments[6] Challenges and Costs - The company faced challenges due to the downturn in the medical industry and executive events, impacting revenue expectations[5] - Legal consulting fees related to executive events amounted to RMB 4.51 million, which was not present in the previous year[6] Data Disclaimer - The company emphasizes the preliminary nature of the financial data, which is subject to audit and final confirmation in the annual report[7]

证券代码：688217 证券简称：睿昂基因 公告编号：2025-016 上海睿昂基因科技股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海睿昂基因科技股份有限公司董事会 2025 年 2 月 25 日 上海睿昂基因科技股份有限公司(以下简称"公司")控股子公司长春技特生物 技术有限公司于近日收到政府补助资金共人民币 180.00 万元，为与收益相关的 政府补助。 二、补助的类型及其对上市公司的影响 根据《企业会计准则第 16 号—政府补助》的相关规定，公司上述获得的政 府补助属于与收益相关的政府补助。上述政府补助未经审计，具体的会计处理以 及对公司损益的影响最终以审计机构年度审计确认后的结果为准。敬请投资者注 意投资风险。 特此公告。 一、获取补助的基本情况 ...

| 回购方案首次披露日 | 2024/2/1 | | | | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 2 月 日~2025 年 2 月 | 19 | 18 日 | | 预计回购金额 | 元 15,000,000 元~20,000,000 | | | | 回购价格上限 | 元/股 49.00 | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | □为维护公司价值及股东权益 | | | | 实际回购股数 | 股 669,621 | | | | 实际回购股数占总股本比例 | 1.20% | | | | 实际回购金额 | 元 17,021,747.99 | | | | 实际回购价格区间 | 22.37 元/股~27.67 元/股 | | | 一、 回购审批情况和回购方案内容 公司分别于 2024 年 1 月 31 日、2024 年 2 月 19 日召开了第二届董事会第二十 一次会议、2024 年第一次临时股东大会，审议通过了《关于以集中竞价交易方式 回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交 ...

关于以集中竞价交易方式回购公司股份的进展公告 证券代码：688217 证券简称：睿昂基因 公告编号：2025-014 上海睿昂基因科技股份有限公司 2025 年 1 月，公司未回购股份。截至 2025 年 1 月 31 日，公司通过上海证券 交易所交易系统以集中竞价交易方式已累计回购公司股份 669,621 股，占公司总 股本 55,855,896 股的比例为 1.20%，回购成交的最高价为 27.67 元/股，最低价为 22.37 元/股，支付的资金总额为人民币 17,021,747.99 元（不含印花税、交易佣 金等交易费用)。 上述回购股份符合相关法律法规的规定和公司回购股份方案的要求。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定及公司回购股份方案，在回购期限内根 据市场情况择机做出回购决策并予以实施，同时根据回购股份事项进展情况及时 履行信息披露义务，敬请广大投资者注意投资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容 ...